Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Peptide-drug conjugates for weight loss maintenance

Project description

Peptide-drug conjugates preventing weight regain

The global obesity epidemic poses a challenge to human health. While effective weight-loss therapies exist, long-term maintenance remains difficult due to the body’s natural drive to regain lost weight. In response to food deprivation, specific hunger-promoting neurons become more excitable, triggering weight recidivism. The ERC-funded PDC-MAIN project aims to prevent this process by developing innovative peptide-drug conjugates (PDCs) that target the cellular mechanisms underlying homeostatic weight regain. By focusing on G protein-coupled receptors (GPCRs) in hypothalamic cells, the project will design GPCR-targeted PDCs to disrupt this cycle. Advanced neurobiological techniques, including fibre photometry, will be used to assess target engagement, while preclinical models will evaluate the potential for sustained weight loss following dietary and pharmacological interventions.

Objective

The worldwide rise in obesity rates is causing significant harm to human health. While effective weight loss therapies are emerging, the challenge of maintaining weight loss remains unresolved. With this project, we will leverage expertise in drug development to engineer novel peptide-drug conjugates designed to obstruct homeostatic weight regain in a cell specific fashion. In the food deprived state, a subset of hunger promoting neurons undergo structural changes that increases excitability and thus drives homeostatic weight regain. Capitalizing on our knowledge of G protein-coupled receptors (GPCRs) expressed in hypothalamic cell populations we will develop GPCR-targeting peptide-drug conjugates specifically designed to obstruct weight recidivism. To evaluate this drug-targeting approach, neurobiological methods including fiber photometry will be employed to confirm target engagement. Preclinical models are used to investigate the translational potential for treatment of weight loss maintenance following dietary and pharmacological weight loss interventions. The molecular mechanisms of action and receptor-target selectivity of the conjugates will be determined using loss-of-function mouse models. Pharmacokinetic properties of lead candidates will be optimized by incorporating chemical half-life extenders. This bridging between medicinal chemistry, neuroscience and pharmacology will give rise to new multimodal molecules targeting homeostatic weight regain mechanisms to address a vastly growing unmet medical need for weight loss maintenance pharmacotherapies.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-COG

See all projects funded under this call

Host institution

KOBENHAVNS UNIVERSITET
Net EU contribution
€ 1 999 610,00
Address
NORREGADE 10
1165 KOBENHAVN
Denmark
Region
Danmark Hovedstaden Byen København
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 999 610,00

Beneficiaries (1)